Around the turn of the millennium, Profs Andrew Coats and Stefan Anker, two leading cardiologists, discovered the use of beta adrenergic blockers in the treatment of cachexia. Numedicus improved on this technology
in the identification of a single isomer of pindolol, and the filing of a patent (now granted worldwide) for the treatment of cachexia.
Espindolol is an improvement on the general utility of beta blockade, since it combines three mechanisms of action in one molecule: beta-1 adrenergic inhibition for the prevention of excess catabolism, partial beta-2 adrenergic agonism to promote anabolism and interaction with 5-HT1A receptors to combat fatigue. This polypharmaceutical approach is valuable in cachexia, a complex condition in which multiple biological pathways are active.
In in vivo testing, espindolol out-performed all other beta blockers in various measures of cachexia; and in a Phase IIb clinical trial, espindolol was shown to significantly reverse weight loss, improve fat free mass, and maintain fat mass in advanced colorectal cancer and non-small cell lung cancer-related cachexia over 4 months.
Most recently, this technology has now been spun out into Actimed Therapeutics.